Fourth-Line Treatment Approved For Gastrointestinal Tumor

The kinase inhibitor ripretinib has received approval as a fourth-line treatment for adults with advanced gastrointestinal stromal tumor (GIST) who already have been treated with 3 or more kinase inhibitors.
Source: JAMA - Category: General Medicine Source Type: research